Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS). The disclosure also provides a method of treating a metabolic disorder or disease by administering a therapeutically effective amount of the 3D-printed tablet to a subject in need thereof.

Abstract: Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS).

Abstract: A transdermal film formulation containing transfersomes incorporated onto the transdermal film is provided. The transfersomes include avanafil, a phospholipid, and an edge activator, wherein the phospholipid to avanafil ratio is from 3.5:1 to 4.5:1 and wherein the edge activator has a hydrophilic-lipophilic (HLB) value of 2-4. Methods of making the transdermal film formulation and methods of delivering avanafil using the transdermal film formulation are also provided.

Abstract: An in situ gel formulation comprising poly lactide-co-?-caprolactone (PLCL), a surfactant with a hydrophilic-lipophilic balance value of 14-15, a plasticizer, and a statin is provided. Methods of treating hyperlipidemia by parenterally administering the in situ gel formulation are also provided.

Abstract: Micelle formulations comprising a tocopherol or derivative thereof, alpha lipoic acid, and a biologically active agent such as vinpocetine are provided. Films for transdermal delivery containing the micelle formulation and methods of treating cognitive and cerebrovascular disorders are also provided.

Abstract: A liquisolid tablet formulation, comprising a microcrystalline cellulose carrier; a silica coating; a crosslinked polyvinylpyrrolidone (PVP) superdisintegrant; a solvent comprising polyethylene glycol (PEG) 200 and caprylocaproyl macrogol-8 glycerides; tadalafil; and dapoxetine, wherein the liquid load factor of the formulation is 0.2-0.4 is provided. Methods of making the liquisolid tablet and methods of using the formulation for the treatment of male sexual dysfunction are also provided.

Abstract: Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.

Abstract: Dapoxetine nanoparticles comprising zein and alpha lipoic acid (ALA) are provided. When present in zein-ALA loaded nanoparticles, dapoxetine exhibits increased bioavailability (compared to conventional formulations) when administered to subjects for the prevention or treatment of premature ejaculation (PE). Thus, lower doses are administered, and side effects are attenuated or eliminated.